Compare CSX Corporation (CSX) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs Nuwellis Inc — how do they compare? CSX Corporation trades at $50.03 (market cap $92.88B), while Nuwellis Inc trades at $1.49 (market cap $522.76K). The key difference: CSX Corporation is far larger — about 177672.4× Nuwellis Inc's market cap, and CSX Corporation pays a 1.12% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| CSX | NUWE | |
|---|---|---|
Market Cap | $92.88B | $522.76K |
Sector | Industrials | Technology |
52-Week High | $53.21 | $220.50 |
52-Week Low | $32.05 | $1.42 |
Enterprise Value | $110.85B | -$1.29M |
Dividend Yield | 1.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $50.27, down 0.85% on the day, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat estimates with EPS of $0.54 versus $0.518 expected, driven by 10% revenue growth and 17% operating income increase. The company raised 2026 guidance to mid-to-high-single-digit revenue growth and margin expansion. Analyst consensus is bullish with 59% buy ratings and a $52.57 price target, implying 4.6% upside from current levels.
Outlook remains positive due to strong volume growth and operational efficiency, but risks include fuel cost pressures and economic sensitivity. The stock offers value through consistent dividends and earnings momentum, though valuation multiples appear elevated with P/E at 29.23. Investors should monitor execution against raised guidance and industry headwinds.
NUWE trades at $1.49, down 8.59% over the past day, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025, with a negative net income margin of -217.22%, though it has shown revenue growth and recent strategic expansions in pediatric care. A recent 35:1 reverse stock split was executed on June 26, 2026.
The outlook remains high-risk due to persistent losses and cash burn, but growth initiatives and new product development offer potential. Key risks include execution challenges and dependence on financing. Analyst sentiment is mixed, with a 50% buy and 50% hold rating among covered analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
